TriangleHEALTH PROFESSIONAL · SOURCE READING
AML induction-type chemotherapy
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of MDS / Disease-Modifying Agents
Induction chemotherapy typically used to treat AML may be used to treat patients with higher-risk MDS with excess blasts.[31] Low-dose cytarabine has benefitted some patients; however, this treatment was associated with a higher infection rate when compared with observation in a randomized trial. No difference in time to progression or OS was observed for patients treated with low-dose cytarabine or supportive care.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice